Te­va’s mi­graine drug can’t stop an­oth­er bad R&D headache as re­searchers scrap a failed PhI­II pro­gram for Ajovy

Te­va’s mar­ket­ing hori­zon for its re­cent­ly ap­proved mi­graine drug just got small­er.

The gener­ics com­pa­ny $TE­VA with a pipeline, Ajovy’s OK last fall was one of the rare R&D bright spots at the com­pa­ny, which has been un­der­go­ing a wrench­ing re­struc­tur­ing in the last 18 months. But re­searchers for the com­pa­ny said on Tues­day that they are scrap­ping a Phase III tri­al for episod­ic clus­ter headaches af­ter the drug (fre­manezum­ab) failed to clear a fu­til­i­ty test.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER